BioCentury
ARTICLE | Clinical News

AngioMab: Phase I halted

May 9, 2005 7:00 AM UTC

ASM halted development of AS1405 in order to transfer resources to its AS1411 aptamer that targets nucleolin. ASM will now attempt to out-license the compound. ...